Objective: To determine the in vitro antimicrobial activity, postantibiotic effect (PAE) and human monocyte activity of grepafloxacin compared with sparfloxacin, ciprofloxacin, clarithromycin, erythromycin and rifampicin against 181 strains of Legionella pneurnophila, nine strains of L. rnicdadei, 10 strains of L. durnoffii, seven strains of L. longbeachae and seven other Legionella strains.
Pneumonia caused by Legionella pneumophila can be severe and life-threatening. The recognition of community-acquired pneumonia (CAP) caused by pathogens such as Legionella spp. is increasing, although it remains relatively uncommon 111. Although the reported frequency of legionella pneumonia often varies markedly from study to study, this variation can probably be explained by the different ways in which the studies are conducted. Thus, a fairly recent European study [2] reports a 3% frequency of community-acquired legionella pneumonia, while another reports that, of all cases of severe CAP requiring patient hospitalization, about 4%) of cases are caused by L. pneumophila and other Legionella spp. [3] . L. pneumophila is the species most commonly associated with legionella pneumonia.
If it is treated promptly, mortality rates associated with community-acquired legionella pneumonia, in otherwise healthy individuals, are low (5%). However, this mortality rate increases up to 15-30% among untreated patients in the same population 1. 11.
Antimicrobial therapy for CAP caused by Legionella spp., as for other intracellular pathogens causing atypical infections, is dictated by the facultative intracellular nature of these bacteria; only agents achieving intracellular penetration are likely to be effective. Antibiotic efficacy is dependent on the ability to penetrate phagocytes and on the suitability of the intracellular environment for expression of drug activity 151. Consequently, serum drug concentrations or serum bactericidal activities may be relatively unimportant, and susceptibility testing using intracellular models may be used to augment standard MIC assays.
Erythromycin, alone or in combination with agents such as rifampicin, is the usual treatment of choice for legionella pneumonia, though the newer macrolides, clarithromycin and azithromycin, are also effective, and offer improved bioavailability, drug interaction and dose regimen profiles. Azithromycin exhibits similar activity to erythromycin against extracellular L. pneumopkila, but is bactericidal or irreversibly inhibitory against the intracellular pathogen, in contrast to the solely reversible inhibition seen with erythromycin [6] . Azithromycin also demonstrates enhanced efficacy compared with clarithromycin [7] . While rifampicin is remarkably active against both extra-and intracellular Legionella spp., it too is reversibly inhibitory and its use as monotherapy is discouraged on the theoretical grounds of possible emergence of resistance [4] . In fact, the use of rifampicin as sole therapy for legionnaires' disease has not been reported 141.
The fluoroquinolone antibiotics also exhibit clinical efficacy in legionnaires' disease and, as a class, have the greatest activity against L. pneumopkila in experimental models [4] . Their excellent activity against intracellular L. pneumophila is consistently higher than that obtained with erythromycin [4] . Furthermore, in contrast to the macrolides (with the possible exception of azithromycin), they are bactericidal rather than bacteriostatic [4] . Ofloxacin, pefloxacin and ciprofloxacin have all been used for the treatment of legionnaires' disease.
As antimicrobial resistance patterns to respiratory pathogens continue to change, there have been increased attempts to develop new agents with extended and improved spectra of activity, effective against a wide range of causative pathogens. This is important in relation to the empirical setting in which antibiotics for respiratory tract infections are commonly prescribed. Grepailoxacin is a new, broad-spectrum fluoroquinolone with improved Gram-positive activity over ciprofloxacin and potent in vitro activity against many Gram-negative and intracellular pathogens [8, 9] . In addition, levels of grepafloxacin in bronchial mucosa, epithelial lining fluid and macrophages have been found to be significantly higher than the mean serum concentration [lo] . These levels attained at the site of respiratory tract infection exceed those reported for other fluoroquinolones, and are considerably higher than previously reported MIC90 levels for common respiratory pathogens. This agent would, therefore, appear to be well suited for the treatment of legionella infection. Other new fluoroquinolones have potent in vitro activity against Legionella, including levofloxacin, sparfloxacin, and trovafloxacin [l 1 ,121. These agents also penetrate well into respiratory tissues, although the concentrations achieved are lower than those observed with grepafloxacin [13-151. In order to evaluate the potential of grepadoxacin, this study set out to compare the MIC, postantibiotic effect (PAE) and human monocyte activity of grepafloxacin, spadoxacin, ciprofloxacin, erythromycin, clarithromycin and rifampicin against a variety of Legionella species.
MATERIALS AND METHODS

Susceptibility testing Isolates
Legionella isolates from the human respiratory tract and environmental sources were grown to produce pure cultures on buffered charcoal yeast extract agar. The organisms investigated were L. [16] .
Antibiotics
Standard antibiotic reference powders were provided by the following sources: grepafloxacin, GlaxoWellcome, Greenford, UK; sparfloxacin, Rh8ne-Poulenc Rorer Co., MontrCal, Canada; ciprofloxacin, Miles Pharmaceuticals, Etobicoke, Canada; clarithromycin, Abbott Laboratories, Chicago, Illinois, USA; rifampicin and erythromycin, Sigma, Mississauga, Ontario, Canada.
MIC determination
MICs were determined by standard, two-fold agar dilution using buffered yeast extract (BYE) agar as previously described by Edelstein and Edelstein [6] . Endpoints were expressed as the lowest concentrations of antibiotic that completely inhibited visible growth. The inoculum was prepared overnight by addng pure colonies to sterile water to a turbidity of no. 1
McFarland standard. The inoculum was diluted lo-', and around lo4 CFU were plated onto BYE agar containing doubling dilutions of antibiotics fkom 0.004 to 256 mg/L. Plates were incubated at 35OC for 48 h. Pseudomonas aeruginosa ATCC 27853 and L. pneumophila ATCC 33152 were used as reference strains.
Determination of PAE
PAE was determined using the broth technique described by Craig 1171. Antibiotics were diluted in sterile water to give a concentration 100-fold higher than the test concentration. A 100-pL aliquot of this solution was added to 8.9 mL BYE prewarmed to 37°C. To mimic achievable serum concentrations as closely as possible, all strains were exposed to antibiotic concentrations four times higher than the MIC.
Colonies of Lcgionella were inoculated in BYE and incubated at 37°C overnight to obtain test cultures in the logarithmic phase of growth. A 1-mL aliquot of each culture was then added to each antibiotic solution and to 9 mL of control medium containing no antibiotic. These dilutions resulted in a final concentration of 106-107 CFU/mL. In all cases, a residual antibiotic control and a control without antibiotic were included; all experiments were conducted in duplicate.
Tubes containing the antibiotic and test cultures were incubated in a shaking water bath at 37°C for 1 h. Antibiotic was then removed by three consecutive centrifugations at l2OOg for 10 min into fresh broth, and the tubes were maintained in the water-bath. Bacterial counts (CFU/mL) were performed on all cultures at time 0, before and after washing, and every hour until turbidity developed. Counts were mapped on a graph and PAE was calculated using the formula:
PAE=T-C where P t i m e taken for the count in the test culture to increase 1 loglo above the count obtained immediately after antibiotic removal, and C= time taken for the count in the control culture to increase 1 loglo above the count obtained immediately after the same procedure in this culture.
Determination of human monocyte activity
Human monocyte activity was assayed using the mononuclear cells described by Honvitz [18] . Heparinized blood was prepared by centrifuging at 1100 rev/min for 15 min; plasma was removed and replaced with phosphate-buffered saline and dextran 2%. The mononuclear cell fraction was obtained by further centrifugation as previously described [18] , separated from other cells by adherence on a Petri dish, and kept in RPMI 1640 [18] until required. Antibiotics were diluted as for PAE assessment, and a 100-pL aliquot was added to 2.0 mL RPMI 1640 + serum culture medium pre-warmed to 37°C. All strains were exposed to antibiotic concentrations twice the MIC. Controls without antibiotic ? human monocytes were included and all assays were done in duplicate.
RPMI 1640 medium containing 15%) fresh human serum (pH 6.85-6.95 a t 37°C) was inoculated with 2 niL of RPMI 1640 medium containing 5 X 106 mononuclear cells. Legionella colonies were inoculated in BYE and incubated at 37°C overnight to obtain test cultures in the logarithmic phase of growth. An inoculum of 106-107 CFU/mL of Legionella was then added to each of the antibiotic solutions, and to 2.0 mL of control medium containing no antibiotic. These dilutions resulted in a final concentration of 2.5 x lo4 CFU/mL. The intracellular location of the Legionella strains was confirmed by using Gienisa's stain.
Cultures were incubated in a shaking water-bath at 37°C for 1 h. After 48 h, the cultures were washed to remove the antibiotic, and cultures were split into two groups: one was reincubated with the same antibiotic, and the second was incubated without the antibiotic. After this time, the cultures were maintained under stationary conditions for 4-5 days at 37°C in 5% CO2. Bacterial counts (CFU/mL) were performed on all cultures at time 0, before and after washing, and every day in triplicate. Bacterial counts were then mapped on a graph or tabulated.
Susceptibility testing
The activity of the study antibiotics against L. pneurnophila serogroups 1-8 is shown in Table 1 In general, L. pneirmophila serogroups 6-8 were more susceptible to grepafloxacin (MICw 0.008 mg/L) than were serogroups 1-5 (MICyo 0.016-0.03 mg/L).
The MIC:)os of the test antibiotics against other Legionella species are shown in Table 2 . Grepafloxacin was more active than erythromycin against L. drimojfii and L. longheachae and more active than both erythromycin and clarithromycin against L. micdadei and isolates of other Legionella spp. Compared with ciprofloxacin, grepafloxacin was equally active against L. micdadei and seven isolates of other Legionella spp. and slightly less active against L. dumojii and L. loqbeaclzae.
PAE assessment
The PAE values of test antibiotics obtained with erythromycin-susceptible or -resistant L. ptieiimophila are shown in Table 3 . The PAE of grepafloxacin (3.62 h) against erythromycin-susceptible L. pneumopkila was longer than those of sparfloxacin (0.88 h), erythromycin (0.93 h) and clarithromycin (0.717 h). Moreover, For other Legionella spp. tested, the mean PAE of grepafloxacin against erythromycin-susceptible strains was higher than that of clarithromycin, while for erythroniycin-resistant strains, grepafloxacin's mean PAE was higher than those of both ciprofloxacin and clarithromycin (Table 3 ). The mean PAE of erythromycin against species other than L. pneumophila was longer for erythromycin-susceptible isolates (2.06 h) than for erythromycin-resistant isolates (0.44 h). However, no measurable PAE was observed with erythromycin against erythromycin-susceptible or -resistant L. micdadei and L. drrmo&i or against erythromycinresistant L. bozemanii and L. uudruwthii (data not shown).
Human monocyte activity
Grepafloxacin, sparfloxacin and ciprofloxacin were bactericidal against both erythromycin-susceptible and -resistant intracellular L. pnertmophila ( Table 4) . Bactericidal activity was defined as a >3 log reduction in viable cell numbers (99.9% kill), and this effect was also seen with other Legionella spp. (Table 5 ). The bactericidal activity of grepafloxacin and ciprofloxacin against intracellular L. pneumoplzila continued even after their removal from the medium (Table 6 ).
DISCUSSION
The organisms tested in this study were: L. pnenmophila
(nine) and L. longbenchae (seven). Overall, the results confirm the findings of other studies [9, 19] . The MIC data obtained in this study indicate that grepafloxacin is highly active against most Legionella spp. Grepafloxacin's activity against L. pneumophila serogroup 1 (MIC9o 0.01 6 mg/L) was particularly interesting, as this serogroup demonstrated the least susceptibility to erythromycin (MICso 1.0 mg/L), and WAS the most common strain isolated from patients with nosocomial or community-acquired respiratory tract infections. As anticipated, rifampicin was also found to be very active against the Legionella spp. tested, and was the most highly active agent against L. pneumophila.
Grepafloxacin's activity against L. yneirmophila was 
L. longbeuchae (n=l) Antibiotics were used at concentrations four times the MIC. (5) 2.5 (7) 5.5 (5) Antibiotics were used at concentrations twice the MIC. Antibiotics were used at concentrations twice the MIC.
found to be superior to that of the two macrolides was found to be slightly more active than ciprofloxacin, evaluated, erythromycin and clarithromycin. This but slightly less active than sparfloxacin, against L. activity of fluoroquinolones compared to erythromycin pneurnophila. The clinical efficacy of grepafloxacin has been noted in other studies [20, 21] .
against L. pneurnophila has also been demonstrated in an
In comparison with the two other fluoroquinolones open, non-comparative study of CAP, which included evaluated, ciprofloxacin and sparfloxacin, grepafloxacin 14 patients with L. pneurnophila pneumonia. The results showed that grepafloxacin provided effective, welltolerated treatment in this patient subgroup [22] .
Grepafloxacin demonstrated similar activity to the other study antibiotics against the other Legionella spp. tested. O f all the other species tested, L. dumojii and L. lotgbearhae were the most resistant to grepafloxacin and clarithromycin (MIC90 0.06 mg/L). Erythromycin was even less active against these species. No difference in grepafloxacin or erythromycin susceptibility was noted between isolates obtained from clinical and environmental sources.
PAE is the persistent suppression of bacterial growth after short exposure to an antibiotic. As L. pnertmophila is a facultative, intracellular bacterium which multiplies within phagocytic cells, both PAE and bactericidaVbacteriostatic activity may be expected to have a relationship with antimicrobial dosing regimens. The bactericidal effect and relatively long PAE of grepafloxacin against intracellular L. pneumophila recorded in this study (for both erythromycinsensitive and -resistant strains) combined with its known persistently high tissue concentrations [lo] suggest that these factors may be of clinical relevance for this agent.
Considering what is already known about grepafloxacin's activity against the main respiratory pathogens, and the results of this study against Legionella spp., the agent appears to offer an excellent therapeutic option in the empirical treatment of patients with CAP, including that caused by Legionella spp.
